Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Anavex Lf SC (NQ: AVXL )

11.60 USD +0.09 (+0.78%)
Streaming Delayed Price Updated: 11:33 AM EDT, May 6, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 189,913
Open 11.50
Bid (Size) 11.52 (1)
Ask (Size) 11.60 (2)
Prev. Close 11.51
Today's Range 11.18 - 11.64
52wk Range 3.250 - 28.70
Shares Outstanding 69,487,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021
Conference Call and Webcast To be Held Thursday, May 13, 2021 4:30 pm Eastern Time 
From GlobeNewswire News Releases
Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development
From GlobeNewswire News Releases

Performance

YTD
+119.28%
+119.28%
1 Month
-26.11%
-26.11%
3 Month
+11.75%
+11.75%
6 Month
+82.97%
+82.97%
1 Year
+250.45%
+250.45%

More News

Read More
Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference
From GlobeNewswire News Releases
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
From PR Newswire
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
From GlobeNewswire News Releases
Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference
From GlobeNewswire News Releases
Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021
From GlobeNewswire News Releases
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
From GlobeNewswire News Releases
Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alz
From GlobeNewswire News Releases
Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.